MNG336
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.462
- MITOTIC_SPINDLE+0.460
- G2M_CHECKPOINT+0.433
- ANGIOGENESIS+0.359
- HYPOXIA+0.297
- PI3K_AKT_MTOR_SIGNALING+0.287
- DNA_REPAIR+0.250
- HEDGEHOG_SIGNALING+0.248
- WNT_BETA_CATENIN_SIGNALING+0.235
- PROTEIN_SECRETION+0.195
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.266
- OXIDATIVE_PHOSPHORYLATION-0.246
- KRAS_SIGNALING_DN-0.221
- INTERFERON_GAMMA_RESPONSE-0.175
- INTERFERON_ALPHA_RESPONSE-0.168
- ALLOGRAFT_REJECTION-0.167
- FATTY_ACID_METABOLISM-0.152
- CHOLESTEROL_HOMEOSTASIS-0.150
- MYC_TARGETS_V2-0.132
- BILE_ACID_METABOLISM-0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG471 | — | — | 0.856 |
| 2 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.817 |
| 3 | SRR934906 | — | — | 0.712 |
| 4 | TCGA-FD-A6TC-01A-21R-A33J-07 | — | — | 0.710 |
| 5 | SRR5088907 | — | — | 0.697 |
| 6 | MNG1221 | — | — | 0.695 |
| 7 | MNG1013 | — | — | 0.690 |
| 8 | SRR8613735 | — | E | 0.685 |
| 9 | SRR8942947 | — | — | 0.685 |
| 10 | TCGA-21-A5DI-01A-31R-A26W-07 | — | cohortSQ1 | 0.680 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.462 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.433 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.359 | Remibrutinib | — uncovered |
| HYPOXIA | 0.297 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.287 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.248 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.235 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.195 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.193 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.192 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.188 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.169 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.143 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.125 | Inavolisib | — uncovered |
| APOPTOSIS | 0.118 | Idelalisib | — uncovered |
| COMPLEMENT | 0.116 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.111 | Idelalisib | — uncovered |